VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.

3 Nov 2015

New TSRI study highlights urgent need for new treatments to fight growing cancer metastases

A new study from scientists at The Scripps Research Institute helps explain why cancer metastasis is so hard to stop.

29 Oct 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.

22 Oct 2015

New study from TSRI and Salk points to cause of debilitating nerve disease

Scientists at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies have discovered how a mutant protein triggers nerve damage in a subtype of Charcot-Marie-Tooth (CMT) diseases, a group of currently untreatable conditions that cause loss of function in a person’s hands and feet.

22 Oct 2015

NAM announces election of three new members from UC San Diego School of Medicine

The National Academy of Medicine announced today the election of three new members from University of California, San Diego School of Medicine: Napoleone Ferrara, MD; Christopher K. Glass, MD, PhD; and Roberto Malinow, MD, PhD. Election to NAM is considered among the highest honors in the fields of health and medicine.

20 Oct 2015

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes.

19 Oct 2015

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine.

15 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

The results show that Oraya Therapy is effective in maintaining vision with reduced injections for patients at different stages of their disease—from chronic patients in discontinuous treatment to treatment-naive patients with new diagnosis—and following different treatment pathways.

1 Oct 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.

28 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.

24 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers.

10 Sep 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

A team of researchers in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy (a murine model used to mimic eye disease).

20 Aug 2015

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Their findings are published today in JAMA Ophthalmology.

14 Aug 2015

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension.

10 Aug 2015

VEGF News and Research

Further Reading

Discovery offers promising alternative to current therapies for AMD and ROP

New TSRI study highlights urgent need for new treatments to fight growing cancer metastases

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

CV risk assessment essential for CML TKI trial design

New study from TSRI and Salk points to cause of debilitating nerve disease

NAM announces election of three new members from UC San Diego School of Medicine

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

New drug works better than current treatments for advanced kidney cancer

ILUVIEN continues to show positive results in Europe

Patients with advanced kidney cancer benefit from cabozantinib treatment

Alimera Sciences announces results from ongoing study on ILUVIEN

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

Risk for endophthalmitis no higher with Avastin, finds study

Novel treatment target found for RV failure in PAH

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation